Article
Oncology
Haiyong Peng, Shaolei Yan, Xiaodan Chen, Jiahang Hu, Kaige Chen, Ping Wang, Hongxia Zhang, Xiushi Zhang, Wei Meng
Summary: This study assessed the diagnostic performance and added value of a computer-aided diagnosis (CAD) system for detecting complete response after neoadjuvant chemotherapy in breast cancer patients. The CAD system improved the performance of all radiologists, regardless of experience. Additionally, the molecular typing of breast cancer may influence the diagnostic performance of the CAD system.
FRONTIERS IN ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Sadia Choudhery, Daniel Gomez-Cardona, Christopher P. Favazza, Tanya L. Hoskin, Tufia C. Haddad, Matthew P. Goetz, Judy C. Boughey
Summary: This study extracted volumetric pretreatment MRI radiomics features in breast cancer patients and found that these features were associated with different molecular subtypes, pathological complete response, and residual cancer burden.
ACADEMIC RADIOLOGY
(2022)
Review
Oncology
Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Muriele Bertagna Varuzza, Cassio Murilo Trovo Hidalgo Filho, Vinicius Duval da Silva, Cristiano de Padua Souza, Marcia Maria Chiquitelli Marques
Summary: Breast cancer is the most common cancer in women worldwide, and personalized medicine requires a combination of clinical and molecular characterization for more effective treatment. Current studies aim to develop more personalized therapies to decrease the adverse effects of chemotherapy.
Review
Oncology
Guoshuang Shen, Fuxing Zhao, Xingfa Huo, Dengfeng Ren, Feng Du, Fangchao Zheng, Jiuda Zhao
Summary: The HER2-enriched subtype is a strong predictor of pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant treatment, especially when HER2-targeted agents are used, regardless of the specific agents or additional therapies employed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Fangyuan Zhao, Minoru Miyashita, Masaya Hattori, Toshio Yoshimatsu, Frederick Howard, Kristiyana Kaneva, Ryan Jones, Joshua S. K. Bell, Gini F. Fleming, Nora Jaskowiak, Rita Nanda, Yonglan Zheng, Dezheng Huo, Olufunmilayo I. Olopade
Summary: This study investigated racial disparities in achieving pathologic complete response (pCR) after neoadjuvant chemotherapy in breast cancer patients and identified factors contributing to these disparities. The study found that Black patients had lower odds of achieving pCR compared to White patients in the hormone receptor-negative/ERBB2+ subtype, and they were more likely to have MAPK pathway alterations, a potential mechanism of anti-ERBB2 therapy resistance. Additionally, significant differences in tumor mutational burden and somatic alterations in several genes were observed between primary and residual tumors.
Article
Oncology
S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J. U. Blohmer, J. Furlanetto, D. M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P. A. Fasching, V. Nekljudova, C. Denkert, M. Untch
Summary: Adding durvalumab to neoadjuvant chemotherapy in patients with TNBC significantly improved survival rates, despite a modest increase in pCR, and without a durvalumab adjuvant component.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Jiaojiao Qi, Chenyu Wang, Yongxin Ma, Jiaxing Wang, Guangfei Yang, Yating Wu, Haiyan Wang, Chengrong Mi
Summary: This study explored the potential role of shear wave elastography (SWE) and superb microvascular imaging (SMI) in assessing the response to neoadjuvant chemotherapy (NAC) in breast cancer. The study found that these advanced ultrasound techniques can identify tumor characteristics associated with the pathological response to NAC, and may be useful for early evaluation of treatment effectiveness.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Alberto Ocana, Jose Ignacio Chacon, Lourdes Calvo, Antonio Anton, Mauro Mansutti, Joan Albanell, Maria Teresa Martinez, Ainhara Lahuerta, Giancarlo Bisagni, Begona Bermejo, Vladimir Semiglazov, Marc Thill, Arlene Chan, Serafin Morales, Jesus Herranz, Ignacio Tusquets, Massimo Chiesa, Rosalia Caballero, Pinuccia Valagussa, Giampaolo Bianchini, Emilio Alba, Luca Gianni
Summary: This study found an association between neutrophil-to-lymphocyte ratio (dNLR) and pathological complete response (pCR) in triple-negative breast cancer (TNBC) patients receiving neoadjuvant chemotherapy. High baseline and end of treatment (EOT) dNLR were correlated with lower likelihood of pCR.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xiaoyan Qian, Meng Xiu, Qing Li, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Qiao Li, Shanshan Chen, Peng Yuan, Fei Ma, Binghe Xu, Pin Zhang
Summary: The predictive factors of recurrence in breast cancer patients achieving pathological complete response (pCR) and near-pathological complete response (near-pCR) include clinical N3 (cN3) before neoadjuvant chemotherapy (NAC) as an independent risk factor, whereas tumor size before NAC, subtypes of breast cancer, and chemotherapy regimens did not show significant associations with recurrence-free survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jens Huober, Marion van Mackelenbergh, Andreas Schneeweiss, Fenja Seither, Jens-Uwe Blohmer, Carsten Denkert, Hans Tesch, Claus Hanusch, Christoph Salat, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Christian Jackisch, Mattea Reinisch, Bianca Lederer, Keyur Mehta, Theresa Link, Valentina Nekljudova, Sibylle Loibl, Michael Untch
Summary: This retrospective pooled analysis aimed to identify factors predicting relapse in breast cancer patients with a pathologic complete response (pCR). A total of 2066 patients with pCR from five neoadjuvant GBG/AGO-B trials were included. The study found that positive lymph nodes, lobular histology, and clinical nodal involvement predicted a higher risk of disease-free survival events in patients with triple-negative tumors. Additionally, HER2-positive cT3/4 tumors were associated with a significantly higher risk of relapse. Initial tumor load and histological type were identified as predictors of relapse in patients with pCR.
Article
Immunology
Yi Xiao, Jiahan Ding, Dachang Ma, Sheng Chen, Xun Li, Keda Yu
Summary: This study found that the HER2/CEP17 ratio, CD8 levels, and histological grade were significantly correlated with pathological complete response (pCR) in dual-targeted neoadjuvant treatment. The combined model using these three markers provided a better predictive value for pCR than the individual markers alone, indicating that the immunological effect partially mediates the predictive impact of neoadjuvant treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Summary: A meta-analysis showed that neoadjuvant chemoimmunotherapy in TNBC patients is associated with higher pathological complete response rate, regardless of PD-L1 status.
Article
Medicine, Research & Experimental
Fengling Li, Yongquan Yang, Yani Wei, Ping He, Jie Chen, Zhongxi Zheng, Hong Bu
Summary: The deep learning-based pCR score derived from histological images predicts pCR in breast cancer patients undergoing neoadjuvant chemotherapy more accurately than conventional biomarkers such as sTILs and subtype, showing great potential for precise patient stratification.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Bei Qian, Jing Yang, Jun Zhou, Longqing Hu, Shoupeng Zhang, Min Ren, Xincai Qu
Summary: This study developed and validated a nomogram for predicting the probability of pathological complete response (pCR) in breast cancer (BC) patients after neoadjuvant chemotherapy (NACT) based on clinicopathological features. The nomogram showed good discrimination, calibration, and clinical usefulness, and could be used to personalize the prediction of pCR in BC patients treated with NACT.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Sara P. Myers, Gillian M. Ahrendt, Joanna S. Lee, Jennifer G. Steiman, Atilla Soran, Ronald R. Johnson, Priscilla F. McAuliffe, Emilia J. Diego
Summary: The study revealed that breast pCR and ypN0 primarily occurred in HER2+ and TNBC subtypes, and factors such as age, tumor subtype, and clinical stage were associated with ypN0. The impact of cN status on ypN0 varied among different tumor subtypes.
ANNALS OF SURGICAL ONCOLOGY
(2021)